Sign In
Buy TECH
$71.36
+0.0600 (+0.0842%)
At Close: Jul 13, 2026
QGEN vs. TECH: Which Stock Should Value Investors Buy Now?
12:52pm, Thursday, 08'th Apr 2021
QGEN vs. TECH: Which Stock Is the Better Value Option?
Bio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess
07:00am, Thursday, 08'th Apr 2021
MINNEAPOLIS, April 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system tha
Bio-Techne Completes Acquisition of Asuragen, Inc.
04:01pm, Tuesday, 06'th Apr 2021
MINNEAPOLIS, April 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of
Bio-Techne To Host Conference Call On May 6, 2021 To Announce Third Quarter 2021 Financial Results
07:00am, Tuesday, 06'th Apr 2021
MINNEAPOLIS, April 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, May 6, 2021, at 8:00 a.m. CDT to
Bio-Techne Announces Launch of Cultrex UltiMatrix BME to Support Organoid and Pluripotent Stem Cell Cultures
07:00am, Monday, 29'th Mar 2021
MINNEAPOLIS, March 29, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an
Bio-Techne Announces Receipt of COVID-19 Innovation Award from CiteAb
07:00am, Friday, 26'th Mar 2021
MINNEAPOLIS, March 26, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its R&D Systems and Novus brands have been named winners of the CiteAb COVID-19 Innovation Award
Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test
07:00am, Tuesday, 23'rd Mar 2021
MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diag
Bio-Techne Announces ISO 9001:2015 Certification for its Bristol Manufacturing Facility.
07:00am, Monday, 15'th Mar 2021
MINNEAPOLIS, March 15, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagn
NEW YORK, March 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today it has been named
Bio-Techne Scoops Up Genetics And Oncology-Focused Diagnostics Firm
06:37am, Thursday, 04'th Mar 2021
Bio-Techne Corp (NASDAQ: TECH) has agreed to acquire Asuragen Inc, a provider of genetic carrier screening and oncology testing kits. The deal value includes an initial consideration of $215 million
Bio-Techne to Acquire Asuragen
04:45pm, Wednesday, 03'rd Mar 2021
MINNEAPOLIS and AUSTIN, Texas, March 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research an
Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America
07:30am, Monday, 08'th Feb 2021
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne C
Bio-Techne Corporation (TECH) CEO Charles Kummeth on Q2 2021 Results - Earnings Call Transcript
02:56pm, Tuesday, 02'nd Feb 2021
Bio-Techne Corporation (TECH) CEO Charles Kummeth on Q2 2021 Results - Earnings Call Transcript
Techne (TECH) Q2 Earnings and Revenues Top Estimates
08:20am, Tuesday, 02'nd Feb 2021
Techne (TECH) delivered earnings and revenue surprises of 19.12% and 9.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Bio-Techne: Q2 Earnings Insights
07:08am, Tuesday, 02'nd Feb 2021
Shares of Bio-Techne (NASDAQ:TECH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 50.00% year over year to $1.62, which beat the estimate of
